Judgment rendered on July 16, 2021 in the proceedings between Biophytis and Negma Group Ltd by the Execution Judge from the Paris Court of JusticeRead the presse release
News
JULY 12, 2021
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
Read the press release
JULY 8, 2021
Biophytis Reinforces Leadership Teams with Three Senior AppointmentsRead the press release
JUNE 30, 2021
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 StudyRead the presse release
JUNE 30, 2021
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021Read the press release
JUNE 18, 2021
Biophytis announces new convertible bonds financing up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million Read the press release
MAY 28, 2021
Interview of Stanislas Veillet on Boursier.comRead the interview
12 MAY 2021
Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim AnalysisRead the press release
MAY 11, 2021
Results of the Combined General Meeting on May 10, 2021Read the press release
APRIL 30, 2021
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholdersRead the press release
APRIL 29, 2021
Biophytis receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMDRead the press release
APRIL 27, 2021
Biophytis – Convening of Another Combined General Meeting at a Later DateRead the press release
APRIL 26, 2021
Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021Read the presse release
April 19, 2021
Interview of Stanislas Veillet, CEO of Biophytis on La Bourse ou la Vide.com (in French).
APRIL 13, 2021
Biophytis Identifies False Report Regarding COVA StudyRead the Press Release
APRIL 7, 2021
Stanislas Veillet, CEO of Biophytis, reviews the company’s latest news in this interview with Laurent Grassin from Journal des Biotechs, covering listing on Nasdaq, Covid-19 clinical studies, expected clinical data in sarcopenia and the legal case with Negma. You can see the interview here
MARCH 22, 2021
Biophytis gives updates on its Phase 2-3 COVA study on COVID-19
MARCH 19, 2021
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd
March 10, 2021
Biophytis AGM meeting will take place on April 26, 2021. Read the Press Release
February 26, 2021
Biophytis Reports 2020 Full Year Results. Read the Press Release
February 17, 2021
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium. Read the Press Release
February 15, 2021
Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market. Read the Press Release
FEBRUARY 10, 2021
Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext.Read the Press Release
FEBRUARY 10, 2021
Biophytis Announces Temporary Trading Halt of its Shares and Share Warrants on Euronext Growth. Read the Press Release
February 10, 2021
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market. Read the Press Release
February 3, 2021
Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing. Read the Press Release
February 3, 2021
Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”). Read the Press Release
January 20, 2021
Biophytis Announces Public Filing of a Registration Statement for Proposed Initial Public Offering in the United States. Read the Press Release
JANUARY 19, 2021
Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States. Read the Press Release
JANUARY 19, 2021
Biophytis receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19. Read the Press Release
January 7, 2021
Biophytis to Participate in Upcoming Investor & Partnering Conferences During J.P. Morgan Week 2021. Read the Press Release